All Stories

  1. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine

    Article • Expert Review of Anticancer Therapy, May 2019, Taylor & Francis

    Professor Godefridus J Peters, Robin van den Borg

  2. RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment

    Article • Expert Opinion on Investigational Drugs, March 2019, Taylor & Francis

    Elisa Giovannetti, Professor Godefridus J Peters

  3. DNA methyltransferases expression in normal tissues and various human cancer cell lines, xenografts and tumors.

    Article • Nucleosides Nucleotides & Nucleic Acids, January 2019, Taylor & Francis

    Professor Godefridus J Peters

  4. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor

    Article • Nucleosides Nucleotides & Nucleic Acids, January 2019, Taylor & Francis

    Professor Godefridus J Peters

  5. Personalized medicine in rheumatoid arthritis: methotrexate polyglutamylation revisited

    Article • Expert Review of Precision Medicine and Drug Development, September 2018, Taylor & Francis

    Professor Godefridus J Peters, Renske Hebing

  6. Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib

    Article • OncoTargets and Therapy, September 2017, Dove Medical Press

    Professor Godefridus J Peters

  7. Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer

    Article • Expert Opinion on Drug Metabolism & Toxicology, July 2017, Taylor & Francis

    Professor Joseph Sweeney, Professor Godefridus J Peters

  8. Pharmacological factors affecting accumulation of gemcitabine’s active metabolite, gemcitabine triphosphate

    Article • Pharmacogenomics, June 2017, Future Medicine

    Professor Godefridus J Peters

  9. New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?

    Article • OncoTargets and Therapy, October 2016, Dove Medical Press

    Professor Godefridus J Peters, Elisa Giovannetti

  10. Drug transport and metabolism of novel anticancer drugs

    Article • Expert Opinion on Drug Metabolism & Toxicology, May 2015, Informa Healthcare

    Professor Godefridus J Peters

  11. Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters

    Article • Expert Opinion on Drug Metabolism & Toxicology, January 2015, Informa Healthcare

    Professor Godefridus J Peters

  12. Novel insights in folate receptors and transporters: implications for disease and treatment of immune diseases and cancer

    Article • Pteridines, January 2015, De Gruyter

    Professor Godefridus J Peters

  13. Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib

    Article • Current Drug Targets, December 2014, Bentham Science Publishers

    Professor Godefridus J Peters

  14. EZH2 (enhancer of zeste homolog 2 (Drosophila))

    Article • Atlas of Genetics and Cytogenetics in Oncology and Haematology, November 2014, INIST-CNRS

    Professor Godefridus J Peters

  15. miR-211 Modulates Gemcitabine Activity Through Downregulation of Ribonucleotide Reductase and Inhibits the Invasive Behavior of Pancreatic Cancer Cells

    Article • Nucleosides Nucleotides & Nucleic Acids, April 2014, Taylor & Francis

    Professor Godefridus J Peters

  16. Radiosensitization by Thymidine Phosphorylase Inhibitor in Thymidine Phosphorylase Negative and Overexpressing Bladder Cancer Cell Lines

    Article • Nucleosides Nucleotides & Nucleic Acids, April 2014, Taylor & Francis

    Professor Godefridus J Peters

  17. Selection of the Best Blood Compartment to Measure Cytidine Deaminase Activity to Stratify for Optimal Gemcitabine or Cytarabine Treatment

    Article • Nucleosides Nucleotides & Nucleic Acids, April 2014, Taylor & Francis

    Professor Godefridus J Peters, joseph ciccolini

  18. Novel Developments in the Use of Antimetabolites

    Article • Nucleosides Nucleotides & Nucleic Acids, April 2014, Taylor & Francis

    Professor Godefridus J Peters

  19. Proceedings of the 15th International Symposium on Purine and Pyrimidine Metabolism in Man

    Article • Nucleosides Nucleotides & Nucleic Acids, April 2014, Taylor & Francis

    Professor Godefridus J Peters

  20. Novel Developments in Metabolic Disorders of Purine and Pyrimidine Metabolism and Therapeutic Applications of Their Analogs

    Article • Nucleosides Nucleotides & Nucleic Acids, April 2014, Taylor & Francis

    Professor Godefridus J Peters

  21. Assessment of Mercaptopurine (6MP) Metabolites and 6MP Metabolic Key-Enzymes in Childhood Acute Lymphoblastic Leukemia

    Article • Nucleosides Nucleotides & Nucleic Acids, April 2014, Taylor & Francis

    Professor Godefridus J Peters

  22. USP1 (ubiquitin specific peptidase 1)

    Article • Atlas of Genetics and Cytogenetics in Oncology and Haematology, April 2014, INIST-CNRS

    Professor Godefridus J Peters

  23. MIR211 (microRNA 211)

    Article • Atlas of Genetics and Cytogenetics in Oncology and Haematology, November 2013, INIST-CNRS

    Professor Godefridus J Peters

  24. Cancer therapeutics and research: novel developments

    Article • journal of cancer therapeutics and research, January 2013, Herbert Publications PVT LTD

    Professor Godefridus J Peters

  25. Effect of staurosporine and ucn-01 on gemcitabine cytotoxicity in relation to cell cycle effects and p53 status

    Article • journal of cancer therapeutics and research, January 2012, Herbert Publications PVT LTD

    Professor Godefridus J Peters

  26. TYMP (thymidine phosphorylase)

    Article • Atlas of Genetics and Cytogenetics in Oncology and Haematology, November 2011, INIST-CNRS

    Professor Godefridus J Peters

  27. Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine

    Article • British Journal of Pharmacology, May 2011, Wiley

    Professor Godefridus J Peters, Dr Ad A van Bodegraven

  28. Biological Activity of 1-Deazapurine Nucleosides: Role of Deoxycytidine Kinase?

    Article • Nucleosides and Nucleotides, April 1999, Taylor & Francis

    Professor Godefridus J Peters

  29. IN-VITRO SCHEDULE-DEPENDENCY OF EO9 AND MILTEFOSINE IN COMPARISON TO STANDARD DRUGS IN COLON-CANCER CELLS

    Article • International Journal of Oncology, March 1994, Spandidos Publications

    Professor Godefridus J Peters